{
    "relation": [
        [
            "",
            "Maraviroc+ Atazanavir / Ritonavir",
            "Atazanavir / Ritonavir + Emtricitabine / Tenofovir"
        ],
        [
            "Description",
            "Maraviroc 150 milligram (mg) tablets once daily along with atazanavir/ritonavir 300 mg/100 mg tablets once daily were orally administered for 96 weeks.",
            "Atazanavir/ritonavir 300 mg/100 mg tablets once daily along with emtricitabine/tenofovir 200 mg/245 mg tablets once daily were orally administered for 96 weeks."
        ]
    ],
    "pageTitle": "A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00827112?sect=Xl0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989142.82/warc/CC-MAIN-20150728002309-00102-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 857525883,
    "recordOffset": 857508101,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: maraviroc Intervention: Human Immunodeficiency Virus-1 Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: July 11, 2011 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Maraviroc+ Atazanavir / Ritonavir \u00a0 \u00a0 Atazanavir / Ritonavir + Emtricitabine / Tenofovir \u00a0 STARTED \u00a0 \u00a0 65 \u00a0 \u00a0 64 \u00a0 Treated \u00a0 \u00a0 60 \u00a0 \u00a0 61 \u00a0 COMPLETED \u00a0 \u00a0 50 \u00a0 \u00a0 52 \u00a0 NOT COMPLETED \u00a0 \u00a0 15 \u00a0 \u00a0 12 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}